Filtered By:
Condition: Heart Failure
Cancer: Carcinoma
Education: Education
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 8 results found since Jan 2013.
The Association of Arsenic Metabolism with Cancer, Cardiovascular Disease, and Diabetes: A Systematic Review of the Epidemiological Evidence
Conclusions:
Population level of iAs% and DMA%, but not MMA%, were associated with arsenic exposure levels. Overall, study findings suggest that higher MMA% was associated with an increased risk of cancer and cardiovascular disease, while lower MMA% was associated with an increased risk of diabetes and metabolic syndrome. Additional population-based studies and experimental studies are needed to further evaluate and understand the role of arsenic exposure in arsenic metabolism and the role of arsenic metabolism in disease development. https://doi.org/10.1289/EHP577
Received: 01 June 2016
Revised: 26 February 2017
Acce...
Source: EHP Research - August 2, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
EPMA-World Congress 2015
Table of contents
A1 Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma
Jella-Andrea Abraham, Olga Golubnitschaja
A2 Integrated market access approach amplifying value of “Rx-CDx”
Ildar Akhmetov
A3 Disaster response: an opportunity to improve global healthcare
Russell J. Andrews, Leonidas Quintana
A4 USA PPPM: proscriptive, profligate, profiteering medicine-good for 1 % wealthy, not for 99 % unhealthy
Russell J. Andrews
A5 The role of ...
Source: EPMA Journal - May 8, 2016 Category: Global & Universal Source Type: research
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news
A Point ‐based Prediction Model for Cardiovascular Risk in Orthotopic Liver Transplantation: The CAR‐OLT Score
Conclusion: The point‐based CAR‐OLT risk score can identify patients at risk for CVD complications after OLT surgery (available at: www.carolt.us). This score may be useful for identification of candidates for further risk stratification or other management strategies to improve CVD outcomes after OLT. This article is protected by copyright. All rights reserved.
Source: Hepatology - July 1, 2017 Category: Internal Medicine Authors: Lisa B. VanWagner, Hongyan Ning, Maureen Whitsett, Josh Levitsky, Sarah Uttal, John T. Wilkins, Michael M. Abecassis, Daniela P. Ladner, Anton I. Skaro, Donald M. Lloyd ‐Jones Tags: Liver Failure, Cirrhosis and Portal Hypertension Source Type: research
Summary: International Kidney Cancer Symposium
Conclusions:
Ideal ischemia time is 20-25 minutes or less improves short and long term renal function. >25 minutes carried 5 year risk of new onset stage 4 CKD
No differences on GFR for cold vs. warm ischemia times
Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.
No ischemia preserves renal function better than warm.
Longer cold ischemia times were equivalent to shorter warm ischemia times.
Quality and quantity of the remaining kidney is associated with ultimate renal function.
Robotics in RCC Surgery
Gennady Bratslavsky, MD
The opening question ...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news